StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$148.36−1.16 (-0.78%)

Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%

Merck Remicade (infliximab by Quarter

Remicade (infliximab — immunology, legacy ex-U.S. marketing rights) — Worldwide sales ($M) ($M)

QuarterlyAnnual

Merck Remicade (infliximab: $0M in Q4 2025, down 100.0% from a year earlier. That is the lowest of the 40 quarters on record here.

Latest, Q4 2025
0
Period ended Dec 31, 2025
Change on a year earlier
-100.0%
114 in Q4 2024
History
40 quarters
Since Q1 2016
Sources
12
Documents cited below

Where the Q4 2025 figure comes from

Calculated from reported figures: Q4 = full year (10-K) − nine months (10-Q)

Source: Form 10-K (filed 2026-02-24) ↗

Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedRemicade (infliximab — immunology, legacy ex-U.S. marketing rights) — Worldwide sales ($M) ($M)Year on yearSource
Q4 2025Dec 31, 20250-100.0%Form 10-K (filed 2026-02-24) ↗
Q3 2025Sep 30, 20250-100.0%Form 10-Q (filed 2025-11-05) ↗
Q2 2025Jun 30, 20250-100.0%Form 10-Q (filed 2025-08-05) ↗
Q1 2025Mar 31, 20250-100.0%Form 10-Q (filed 2025-05-02) ↗
Q4 2024Dec 31, 2024114-39.0%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q3 2024Sep 30, 202441-4.7%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q2 2024Jun 30, 202435-22.2%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q1 2024Mar 31, 202439-18.7%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q4 2023Dec 31, 2023187+325.0%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q3 2023Sep 30, 202343-12.2%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q2 2023Jun 30, 202345-15.1%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q1 2023Mar 31, 202348-21.3%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q4 2022Dec 31, 202244-34.3%Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q3 2022Sep 30, 202249-32.9%Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q2 2022Jun 30, 202253-29.3%Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q1 2022Mar 31, 202261-28.2%Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗

Breakdown

What makes up remicade (infliximab

Cite this data

StockData. (2026). Merck Remicade (infliximab ($M), quarterly Q1 2016–Q4 2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-remicade

See every metric in the Merck KPI table. Data updated Oct 26, 2026.